These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 36453516)

  • 1. Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients.
    Saygin C; Cannova J; Stock W; Muffly L
    Haematologica; 2022 Dec; 107(12):2783-2793. PubMed ID: 36453516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MRD in ALL: Optimization and Innovations.
    Pierce E; Mautner B; Mort J; Blewett A; Morris A; Keng M; El Chaer F
    Curr Hematol Malig Rep; 2022 Aug; 17(4):69-81. PubMed ID: 35616771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRD in Philadelphia Chromosome-Positive ALL: Methodologies and Clinical Implications.
    Tran V; Salafian K; Michaels K; Jones C; Reed D; Keng M; El Chaer F
    Curr Hematol Malig Rep; 2024 Aug; 19(4):186-196. PubMed ID: 38888822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurable residual disease in acute lymphoblastic leukemia: How low is low enough?
    Logan AC
    Best Pract Res Clin Haematol; 2022 Dec; 35(4):101407. PubMed ID: 36517126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concordance of Next-Generation Sequencing and Multiparametric Flow Cytometry Methods for Detecting Measurable Residual Disease in Adult Acute Lymphoblastic Leukemia: Optimizing Prediction of Clinical Outcomes From a Single-Center Study.
    Ashouri K; Nittur V; Ginosyan AA; Hwang J; Adnani B; Chen D; Savitala-Damerla L; Schiff K; Chaudhary P; Kovach AE; Ladha A; Siddiqi I; Ali A; Woan K; Tam E; Yaghmour G
    Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):e59-e66.e2. PubMed ID: 38061959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurable residual disease study through three different methods can anticipate relapse and guide early interventions in childhood acute lymphoblastic leukemia.
    Ramos Elbal E; Fuster JL; Campillo JA; Galera AM; Cortés MB; Llinares ME; Jiménez I; Plaza M; Martínez Banaclocha H; Galián JA; Blanquer Blanquer M; Martínez Sánchez MV; Muro M; Minguela A
    Clin Transl Oncol; 2024 Jan; 26(1):278-287. PubMed ID: 37368200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal Residual Disease in Acute Lymphoblastic Leukemia: How to Recognize and Treat It.
    Short NJ; Jabbour E
    Curr Oncol Rep; 2017 Jan; 19(1):6. PubMed ID: 28205134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia.
    Kruse A; Abdel-Azim N; Kim HN; Ruan Y; Phan V; Ogana H; Wang W; Lee R; Gang EJ; Khazal S; Kim YM
    Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32033444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurable residual disease of acute lymphoblastic leukemia in allograft settings: how to evaluate and intervene.
    Sun YQ; Li SQ; Zhao XS; Chang YJ
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):453-464. PubMed ID: 32459519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.
    Zhao H; Wei J; Wei G; Luo Y; Shi J; Cui Q; Zhao M; Liang A; Zhang Q; Yang J; Li X; Chen J; Song X; Jing H; Li Y; Hao S; Wu W; Tan Y; Yu J; Zhao Y; Lai X; Yin ETS; Wei Y; Li P; Huang J; Wang T; Blaise D; Xiao L; Chang AH; Nagler A; Mohty M; Huang H; Hu Y
    J Hematol Oncol; 2020 May; 13(1):42. PubMed ID: 32366260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effectiveness of blinatumomab in clearing measurable residual disease in pediatric B-cell acute lymphoblastic leukemia patients detected by next-generation sequencing.
    Gu M; Xia Y; Zhang J; Tang Y; Xu W; Song H; Xu X
    Cancer Med; 2023 Dec; 12(24):21978-21984. PubMed ID: 38063317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry.
    Thörn I; Forestier E; Botling J; Thuresson B; Wasslavik C; Björklund E; Li A; Lindström-Eriksson E; Malec M; Grönlund E; Torikka K; Heldrup J; Abrahamsson J; Behrendtz M; Söderhäll S; Jacobsson S; Olofsson T; Porwit A; Lönnerholm G; Rosenquist R; Sundström C
    Br J Haematol; 2011 Mar; 152(6):743-53. PubMed ID: 21250970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia.
    Hein K; Short N; Jabbour E; Yilmaz M
    Blood Lymphat Cancer; 2022; 12():7-16. PubMed ID: 35340663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparisons of Long-Term Survival and Safety of Haploidentical Hematopoietic Stem Cell Transplantation After CAR-T Cell Therapy or Chemotherapy in Pediatric Patients With First Relapse of B-Cell Acute Lymphoblastic Leukemia Based on MRD-Guided Treatment.
    Hu G; Cheng Y; Zuo Y; Chang Y; Suo P; Jia Y; Lu A; Wang Y; Jiao S; Zhang L; Sun Y; Yan C; Xu L; Zhang X; Liu K; Wang Y; Zhang L; Huang X
    Front Immunol; 2022; 13():915590. PubMed ID: 35734165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival.
    Logan AC; Vashi N; Faham M; Carlton V; Kong K; Buño I; Zheng J; Moorhead M; Klinger M; Zhang B; Waqar A; Zehnder JL; Miklos DB
    Biol Blood Marrow Transplant; 2014 Sep; 20(9):1307-13. PubMed ID: 24769317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematopoietic Cell Transplantation for Philadelphia Chromosome Negative Adult Acute Lymphoblastic Leukemia in the Modern Era of Immune Therapy.
    Yurkiewicz I; Craig J; Muffly L
    Curr Hematol Malig Rep; 2020 Jun; 15(3):187-193. PubMed ID: 32358681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes.
    Huang YJ; Coustan-Smith E; Kao HW; Liu HC; Chen SH; Hsiao CC; Yang CP; Jaing TH; Yeh TC; Kuo MC; Lai CL; Chang CH; Campana D; Liang DC; Shih LY
    J Formos Med Assoc; 2017 Oct; 116(10):774-781. PubMed ID: 28063722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between a 10-color flow cytometric measurable residual disease (MRD) analysis and molecular MRD in adult B-acute lymphoblastic leukemia.
    Singh J; Gorniak M; Grigoriadis G; Westerman D; McBean M; Venn N; Law T; Sutton R; Morgan S; Fleming S
    Cytometry B Clin Cytom; 2022 Mar; 102(2):115-122. PubMed ID: 34806309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How I use next-generation sequencing-MRD to plan approach and prevent relapse after HCT for children and adults with ALL.
    Muffly L; Liang EC; Dolan JG; Pulsipher MA
    Blood; 2024 Jul; 144(3):253-261. PubMed ID: 38728375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
    Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
    Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.